Articles from eXoZymes

October 22 investor event will explore eXoZymes' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead.

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027

Management to host Q2 2026 update at 5PM ET / 2PM PT, today.

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules.

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.